



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : C12N 5/00, C07K 13/00		A1	(11) International Publication Number: WO 91/10727 (43) International Publication Date: 25 July 1991 (25.07.91)
 (21) International Application Number: PCT/US91/00453 (22) International Filing Date: 22 January 1991 (22.01.91) (30) Priority data: 467,888 22 January 1990 (22.01.90) US		 (81) Designated State: KR. Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
 (71) Applicant: LA JOLLA CANCER RESEARCH FOUNDATION [US/US]; 10901 North Torrey Pines Road, La Jolla, CA 92037 (US). (72) Inventors: RUOSLAHTI, Erkki, I. ; P.O. Box 1054, Rancho Santa Fe, CA 92067 (US). YAMAGUCHI, Yu ; 7793 Camino Glorita, San Diego, CA 92122 (US). (74) Agents: CAMPBELL, Cathryn et al.; Pretty, Schroeder, Brueggemann & Clark, 444 South Flower Street, Suite 2000, Los Angeles, CA 90071 (US).			
 (54) Title: INHIBITORS OF CELL REGULATORY FACTORS			
 (57) Abstract			
<p>The present invention provides a method of inhibiting an activity of a cell regulatory factor comprising contacting the cell regulatory factor with a purified polypeptide, wherein the polypeptide comprises the cell regulatory factor binding domain of a protein and wherein the protein is characterized by a leucine-rich repeat of about 24 amino acids. In a specific embodiment, the present invention relates to the ability of decorin, a 40,000 dalton protein that usually carries a glycosaminoglycan chain, to bind TGFβ. The invention also provides a novel cell regulatory factor designated MRF. Also provided are methods of identifying, detecting and purifying cell regulatory factors and proteins which bind and affect the activity of cell regulatory factors.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

Inhibitors of Cell Regulatory Factors

This invention is a continuation-in-part of U.S. Serial No. 07/212,702 filed June 28, 1988, the contents of 5 which are incorporated by reference herein.

This invention was made with support of government grants CA 30199, CA 42507 and CA 28896 from the National Cancer Institute. Therefore, the United States government 10 may have rights in the invention.

FIELD OF INVENTION

This invention relates to cell biology and more 15 specifically to the control of cell proliferation.

BACKGROUND OF THE INVENTION

Proteoglycans are proteins that carry one or more 20 glycosaminoglycan chains. The known proteoglycans carry out a wide variety of functions and are found in a variety of cellular locations. Many proteoglycans are components of extracellular matrix, where they participate in the assembly of cells and effect the attachment of cells to the 25 matrix.

Decorin, also known as PG-II or PG-40, is a small proteoglycan produced by fibroblasts. Its core protein has a molecular weight of about 40,000 daltons. The core has 30 been sequenced (Krusius and Ruoslahti, Proc. Natl. Acad. Sci. USA 83:7683 (1986); Day et al. Biochem. J. 248:801 (1987), both of which are incorporated herein by reference) and it is known to carry a single glycosaminoglycan chain of a chondroitin sulfate/dermatan sulfate type (Pearson, et 35 al., J. Biol. Chem. 258:15101 (1983), which is incorporated herein by reference). The only previously known function for decorin is binding to type I and type II collagen and

its effect on the fibril formation by these collagens (Vogel, et al., *Biochem. J.* 223:587 (1984); Schmidt et al., *J. Cell Biol.* 104:1683, (1987)). Two proteoglycans, biglycan (Fisher et al., *J. Biol. Chem.* 264:4571 (1989)) and fibromodulin, (Oldberg et al., *Embo J.* 8:2601, (1989)) have core proteins the amino acid sequences of which are closely related to that of decorin and they, together with decorin, can be considered a protein family. Each of their sequences is characterized by the presence of a leucine-rich repeat of about 24 amino acids. Several other proteins contain similar repeats. Together all these proteins form a superfamily of proteins (Ruoslahti, *Ann. Rev. Cell Biol.* 4:229, (1988); McFarland et al., *Science* 245:494 (1989)).

15 Transforming growth factor β 's (TGFB) are a family of multi-functional cell regulatory factors produced in various forms by many types of cells (for review see Sporn et al., *J. Cell Biol.* 105:1039, (1987)). Five different TGFB's are known, but the functions of only two, TGFB-1 and 20 TGFB-2, have been characterized in any detail. TGFB's are the subject of U.S. Patent Nos. 4,863,899; 4,816,561; and 4,742,003 which are incorporated by reference. TGFB-1 and TGFB-2 are publicly available through many commercial sources (e.g. R & D Systems, Inc., Minneapolis, MN). These 25 two proteins have similar functions and will be here collectively referred to as TGFB. TGFB binds to cell surface receptors possessed by essentially all types of cells, causing profound changes in them. In some cells, TGFB promotes cell proliferation, in others it suppresses 30 proliferation. A marked effect of TGFB is that it promotes the production of extracellular matrix proteins and their receptors by cells (for review see Keski-Oja et al., *J. Cell Biochem* 33:95 (1987); Massague, *Cell* 49:437 (1987); Roberts and Sporn in "Peptides Growth Factors and Their 35 Receptors" [Springer-Verlag, Heidelberg] in press (1989)).

While $TGFB$ has many essential cell regulatory functions, improper $TGFB$ activity can be detrimental to an organism. Since the growth of mesenchyme and proliferation of mesenchymal cells is stimulated by $TGFB$, some tumor 5 cells may use $TGFB$ as an autocrine growth factor. Therefore, if the growth factor activity of $TGFB$ could be prevented, tumor growth could be controlled. In other cases the inhibition of cell proliferation by $TGFB$ may be detrimental, in that it may prevent healing of injured 10 tissues. The stimulation of extracellular matrix production by $TGFB$ is important in situations such as wound healing. However, in some cases the body takes this response too far and an excessive accumulation of extracellular matrix ensues. An example of excessive 15 accumulation of extracellular matrix is glomerulonephritis, a disease with a detrimental involvement of $TGFB$.

Thus, there exists a critical need to develop 20 compounds that can modulate the effects of cell regulatory factors such as $TGFB$. The present invention satisfies this need and provides related advantages.

SUMMARY OF THE INVENTION

25 The present invention provides a method of inhibiting an activity of a cell regulatory factor comprising contacting the cell regulatory factor with a purified polypeptide, wherein the polypeptide comprises a cell regulatory factor binding domain of a protein and wherein 30 the protein is characterized by a leucine-rich repeat of about 24 amino acids. In a specific embodiment, the present invention relates to the ability of decorin, a 40,000 dalton protein that usually carries a glycosaminoglycan chain, to bind $TGFB$. The invention also 35 provides a novel cell regulatory factor designated Morphology Restoring Factor, (MRF). Also provided are methods of identifying, detecting and purifying cell

regulatory factors and proteins which bind and affect the activity of cell regulatory factors.

BRIEF DESCRIPTION OF THE FIGURES

5 Figure 1 shows expression of decorin cDNA containing a mutation of the serine acceptor site to alanine. COS-1 cultures were transfected with cDNA coding for wild-type decorin (lane 1), decorin in which the serine-4 residue was replaced by an alanine (lane 2), or decorin in which the 10 serine-4 residue was replaced by a threonine (lane 3). Immunoprecipitations were performed with an anti-decorin antibody and medium which was labeled with ^{35}S -sulfate (A) or ^3H -leucine (B). Lane 4 shows an immunoprecipitate from mock transfected COS-1 cultures. Arrow indicates top of 15 gel. The numbers indicate $M_r \times 10^{-3}$ for molecular weight standards.

Figure 2 shows binding of $[^{125}\text{I}]TGF\beta 1$ to decorin-Sepharose.

20 (A) Fractionation of $[^{125}\text{I}]TGF\beta 1$ by decorin-Sepharose affinity chromatography. $[^{125}\text{I}]TGF\beta 1$ (5×10^5 cpm) was incubated in BSA-coated polypropylene tubes with 0.2 ml of packed decorin-Sepharose (●) or gelatin-Sepharose (○) in 2 ml of PBS pH 7.4, containing 1 M NaCl and 0.05% Tween 20. 25 After overnight incubation, the affinity matrices were transferred into BSA-coated disposable columns (Bio Rad) and washed with the binding buffer. Elution was effected first with 3 M NaCl in the binding buffer and then with 8 M urea in the same buffer.

30 (B) Analysis of eluents of decorin-Sepharose affinity chromatography by SDS-polyacrylamide gel under nonreducing conditions. Lane 1: the original $[^{125}\text{I}]$ -labeled $TGF\beta 1$ sample; lanes 2-7: flow through and wash fractions; lanes 8-10: 3 M NaCl fractions; lanes 11-14: 8 M urea

fractions. Arrows indicate the top and bottom of the 12% separating gel.

Figure 3 shows the inhibition of binding of [¹²⁵I]TGF β 1 to decorin by proteoglycans and their core proteins.

(A) Competition of [¹²⁵I]TGF β 1 binding to decorin-coated microtiter wells by recombinant decorin (●), decorin isolated from bovine skin (PGII) (■), biglycan isolated from bovine articular cartilage (PGI) (▲), chicken 10 cartilage proteoglycan (○), and BSA (□). Each point represents the mean of duplicate determinants.

(B) Competition of [¹²⁵I]TGF β 1 binding with chondroitinase ABC-treated proteoglycans and BSA. The concentrations of 15 competitors were expressed as intact proteoglycan. The symbols are the same as in A.

Figure 4 shows neutralization of the growth regulating activity of TGF β 1 by decorin.

(A) Shows inhibition of TGF β 1-induced proliferation of CHO cells by decorin. [³H]Thymidine incorporation assay was performed as described in the legend of Figure 1 in the presence of 5 ng/ml of TGF β -1 and the indicated concentrations of purified decorin (●) or BSA (○). At the 25 concentration used, TGF β -1 induced a 50% increase of [³H]thymidine incorporation in the CHO cells. The data represent percent neutralization of this growth stimulation; i.e. [³H]thymidine incorporation in the absence of either TGF β 1 or decorin = 0%, incorporation in the 30 presence of TGF β but not decorin = 100%. Each point shows the mean \pm standard deviation of triplicate samples.

(B) Shows neutralization of TGF β 1-induced growth inhibition in Mv1Lu cells by decorin. Assay was performed 35 as in A except that TGF β -1 was added at 0.5 ng/ml. This concentration of TGF β -1 induces 50% reduction of

[³H]thymidine incorporation in the Mv1Lu cells. The data represent neutralization of TGF β -induced growth inhibition; i.e. [³H]thymidine incorporation in the presence of neither TGF β or decorin = 100%; incorporation in the presence of 5 TGF β but not decorin = 0%.

Figure 5A shows separation of growth inhibitory activity from decorin-expressing CHO cells by gel filtration. Serum-free conditioned medium of decorin 10 overexpressor cells was fractionated by DEAE-Sephadex chromatography in a neutral Tris-HCl buffer and fractions containing growth inhibitory activity were pooled, made 4M with guanidine-HCl and fractionated on a Sephadex CL-6B column equilibrated with the same guanidine-HCl solution. 15 The fractions were analyzed for protein content, decorin content, and growth regulatory activities. Elution positions of marker proteins are indicated by arrows. BSA: bovine serum albumin (Mr=66,000); CA: carbonic anhydrase (Mr=29,000); Cy:cytochrome c (Mr=12,400); Ap:aprotinin 20 (Mr=6,500); TGF: [¹²⁵I]TGF β 1 (Mr=25,000).

Figure 5B shows identification of the growth stimulatory material from gel filtration as TGF β 1. The growth stimulatory activity from the late fractions from 25 Sephadex 6B (bar in panel A) was identified by inhibiting the activity with protein A-purified IgG from an anti-TGF β antiserum. Data represent percent inhibition of growth stimulatory activity in a [³H]thymidine incorporation assay. Each point shows the mean \pm standard deviation of triplicate 30 determinations. Anti-TGF β 1 (●), normal rabbit IgG (○).

Figure 6 shows micrographs demonstrating a decorin-binding cell regulatory activity that is not suppressed by antibodies to TGF β -1.

DETAILED DESCRIPTION OF THE INVENTION

The invention provides a method of inhibiting an activity of a cell regulatory factor comprising contacting 5 the cell regulatory factor with a purified polypeptide, wherein the polypeptide comprises the cell regulatory factor binding domain of a protein and wherein the protein is characterized by a leucine-rich repeat of about 24 amino acids. Since diseases such as cancer result from 10 uncontrolled cell proliferation, the invention can be used to treat such diseases.

By "cell regulatory factor" is meant a molecule which can regulate an activity of a cell. The cell regulatory 15 factors are generally proteins which bind cell surface receptors and include growth factors. Examples of cell regulatory factors include the five TGF β 's, platelet-derived growth factor, epidermal growth factor, insulin like growth factor I and II, fibroblast growth factor, 20 interleukin-2, nerve growth factor, hemopoietic cell growth factors (IL-3, GM-CSF, M-CSF, G-CSF, erythropoietin) and the newly discovered Morphology Restoring Factor, hereinafter "MRF". Different regulatory factors can be bound by different proteins which can affect the regulatory 25 factor's activity. For example, TGF β -1 is bound by decorin and biglycan, and MRF by decorin.

By "cell regulatory factor binding domain" is meant the fragment of a protein which binds to the cell 30 regulatory factor. While the specific examples set forth herein utilize proteins, it is understood that a protein fragment which retains the binding activity is included within the scope of the invention. Fragments which retain such activity can be recognized by their ability to 35 competitively inhibit the binding of, for example, decorin to TGF β , or of other polypeptides containing leucine-rich repeats to their cognate growth factors. As an example,

fragments can be obtained by digestion of the native polypeptide or by synthesis of fragments based on the known amino acid sequence. Such fragments can then be used in a competitive assay to determine whether they retain binding 5 activity. For example, decorin can be attached to an affinity matrix, as by the method of Example II. Labelled TGFB, and the fragment in question can then be contacted with the affinity matrix and the amount of TGFB bound thereto determined.

10 As used herein, "decorin" refers to a proteoglycan having substantially the structural characteristics attributed to it in Krusius and Ruoslahti, supra. Human fibroblast decorin has substantially the amino acid sequence presented in Krusius and Ruoslahti, supra.
15 "Decorin" refers both to the native composition and to modifications thereof which substantially retain the functional characteristics. Decorin core protein refers to decorin that no longer is substantially substituted with glycosaminoglycan and is included in the definition of
20 decorin. Decorin can be rendered glycosaminoglycan-free by mutation or other means, such as by producing recombinant decorin in cells incapable of attaching glycosaminoglycan chains to a core protein.

25 Since the regulatory factor binding proteins each contain leucine-rich repeats of about 24 amino acids which can constitute 80% of the protein, it is likely that the fragments which retain the binding activity occur in the leucine-rich repeats. However, it is possible the binding
30 activity resides in the carboxy terminal amino acids or the junction of the repeats and the carboxy terminal amino acids.

35 The invention teaches a general method whereby one skilled in the art can identify proteins which can bind to cell regulatory factors or identify cell regulatory factors

which bind to a certain family of proteins. The invention also teaches a general method whereby these novel proteins or known existing proteins can be assayed to determine if they affect an activity of a cell regulatory factor.

5 Specifically, the invention teaches the discovery that decorin and biglycan bind TGF β -1 and MRF and that such binding can inhibit the cell regulatory functions of TGF β -1. Further, both decorin and biglycan are about 80% homologous and contain a leucine-rich repeat of about 24

10 amino acids in which the arrangement of the leucine residues is conserved. As defined each repeat generally contains at least two leucine residues and can contain five or more. These proteoglycans are thus considered members of the same protein family. See Ruoslahti, supra, Fisher

15 et al., J. Biol. Chem., 264:4571-4576 (1989) and Patthy, J. Mol. Biol., 198:567-577 (1987), all of which are incorporated by reference. Other known or later discovered proteins having this leucine-rich repeat, i.e., fibromodulin, would be expected to have a similar cell

20 regulatory activity. The ability of such proteins to bind cell regulatory factors could easily be tested, for example by affinity chromatography or microtiter assay as set forth in Example II, using known cell regulatory factors, such as TGF β -1. Alternatively, any later discovered cell

25 regulatory factor could be tested, for example by affinity chromatography using one or more regulatory factor binding proteins. Once it is determined that such binding occurs, the effect of the binding on the activity of all regulatory factors can be determined by methods such as growth assays

30 as set forth in Example III. Moreover, one skilled in the art could simply substitute a novel cell regulatory factor for TGF β -1 or a novel leucine-rich repeat protein for decorin or biglycan in the Examples to determine their activities. Thus, the invention provides general methods

35 to identify and test novel cell regulatory factors and proteins which affect the activity of these factors.

The invention also provides a novel purified compound comprising a cell regulatory factor attached to a purified polypeptide wherein the polypeptide comprises the cell regulatory factor binding domain of a protein and the 5 protein is characterized by a leucine-rich repeat of about 24 amino acids.

The invention further provides a novel purified protein, designated MRF, having a molecular weight of about 10 20 kd, which can be isolated from CHO cells, copurifies with decorin under nondissociating conditions, separates from decorin under dissociating conditions, changes the morphology of transformed 3T3 cells, and has an activity which is not inhibited with anti-TGF β -1 antibody. 15 Additionally, MRF separates from TGF β -1 in HPLC.

The invention still further provides a method of purifying a cell regulatory factor comprising contacting the regulatory factor with a protein which binds the cell 20 regulatory factor and has a leucine-rich repeat of about 24 amino acids and to purify the regulatory factor which becomes bound to the protein. The method can be used, for example, to purify TGF β -1 by using decorin.

25 The invention additionally provides a method of treating a pathology caused by a TGF β -regulated activity comprising contacting the TGF β with a purified polypeptide, wherein the polypeptide comprises the TGF β binding domain of a protein and wherein the protein is characterized by a 30 leucine-rich repeat of about 24 amino acids, whereby the pathology-causing activity is prevented or reduced. While the method is generally applicable, specific examples of pathologies which can be treated include a cancer, a fibrotic disease, and glomerulonephritis. In cancer, for 35 example, decorin can be used to bind TGF β -1, destroying TGF β -1's growth stimulating activity on the cancer cell.

Finally, a method of preventing the inhibition of a cell regulatory factor is provided. The method comprises contacting a protein which inhibits an activity of a cell 5 regulator factor with a molecule which inhibits the activity of the protein. For example, decorin could be bound by a molecule, such as an antibody, which prevents decorin from binding TGF β -1, thus preventing decorin from inhibiting the TGF β -1 activity. Thus, the TGF β -1 wound 10 healing activity could be promoted by binding TGF β -1 inhibitors.

It is understood that modifications which do not substantially affect the activity of the various molecules 15 of this invention including TGFB, MRF, decorin, biglycan and fibromodulin are also included within the definition of those molecules. It is also understood that the core proteins of decorin, biglycan and fibromodulin are also included within the definition of those molecules.

20 The following examples are intended to illustrate but not limit the invention.

EXAMPLE I

25 EXPRESSION AND PURIFICATION OF RECOMBINANT DECORIN
AND DECORIN CORE PROTEIN

Expression System

30 The 1.8 kb full-length decorin cDNA described in Krusius and Ruoslahti, Proc. Natl. Acad. Sci. USA 83:7683 (1986), which is incorporated herein by reference, was used for the construction of decorin expression vectors. For the expression of decorin core protein, cDNA was 35 mutagenized so the fourth codon, TCT, coding for serine, was changed to ACT coding for threonine, or GCT coding for

alanine. This was engineered by site-directed mutagenesis according to the method of Kunkel, Proc. Natl. Acad. Sci USA 82:488 (1985), which is incorporated herein by reference. The presence of the appropriate mutation was 5 verified by DNA sequencing.

The mammalian expression vectors pSV2-decorin and pSV2-decorin/CP-thr4 core protein were constructed by ligating the decorin cDNA or the mutagenized decorin cDNA 10 into 3.4 kb HindIII-Bam HI fragment of pSV2 (Mulligan and Berg, Science 209:1423 (1980), which is incorporated herein by reference).

Dihydrofolate reductase (dhfr)-negative CHO cells 15 (CHO-DG44) were cotransfected with pSV2-decorin or pSV2-decorin/CP and pSV2dhfr by the calcium phosphate coprecipitation method. The CHO-DG44 cells transfected with pSV2-decorin are deposited with the American Type Culture Collection under Accession Number CRL 10332. The 20 transfected cells were cultured in nucleoside-minus alpha-modified minimal essential medium (α -MEM), (GIBCO, Long Island) supplemented with 9% dialyzed fetal calf serum, 2 mM glutamine, 100 units/ml penicillin and 100 μ g/ml streptomycin. Colonies arising from transfected cells were 25 picked using cloning cylinders, expanded and checked for the expression of decorin by immunoprecipitation from 35 SO₄-labeled culture supernatants. Clones expressing a substantial amount of decorin were then subjected to gene amplification by stepwise increasing concentration of 30 methotrexate (MTX) up to 0.64 μ M (Kaufman and Sharp, J. Mol. Biol. 159:601 (1982), which is incorporated herein by reference). All the amplified cell lines were cloned either by limiting dilution or by picking single MTX 35 resistant colonies. Stock cultures of these established cell lines were kept in MTX-containing medium. Before use in protein production, cells were subcultured in MTX-minus medium from stock cultures and passed at least once in this

medium to eliminate the possible MTX effects.

Alternatively, the core protein was expressed in COS-1 cells as described in Adams and Rose, Cell 41:1007, 5 (1985), which is incorporated herein by reference. Briefly, 6-well multiwell plates were seeded with 3-5x10⁵ cells per 9.6 cm² growth area and allowed to attach and grow for 24 hours. Cultures were transfected with plasmid DNA when they were 50-70% confluent. Cell layers were washed 10 briefly with Tris buffered saline (TBS) containing 50 mM Tris, 150 mM NaCl pH 7.2, supplemented with 1 mM CaCl₂ and 0.5 mM MgCl₂ at 37°C to prevent detachment. The wells were incubated for 30 minutes at 37°C with 1 ml of the above solution containing 2 µg of closed circular plasmid DNA and 15 0.5 mg/ml DEAE-Dextran (Sigma) of average molecular mass of 500,000. As a control, cultures were transfected with the pSV2 expression plasmid lacking any decorin insert or mock transfected with no DNA. Culture were then incubated for 3 hours at 37°C with Dulbecco's Modified Eagle's medium 20 (Irvine Scientific) containing 10% fetal calf serum and 100 µM chloroquine (Sigma), after removing the DNA/TBS/DEAE-Dextran solution and rinsing the wells with TBS. The cell layers were then rinsed twice and cultured in the above medium, lacking any chloroquine, for approximately 36 25 hours. WI38 human embryonic lung fibroblasts were routinely cultured in the same medium.

COS-1 cultures were radiolabeled 36-48 hours after transfection with the plasmid DNAs. All radiolabeled 30 metabolic precursors were purchased from New England Nuclear (Boston, MA). The isotopes used were ³⁵S-sulfate (460 mCi/ml), L-[3,4,5-³H(N)] -leucine (140 Ci/ml) and L-[¹⁴C(U)] - amino acid mixture (product number 445E). Cultures were labeled for 24 hours in Ham's F-12 medium 35 (GIBCO Labs), supplemented with 10% dialyzed fetal calf serum, 2 mM glutamine and 1 mM pyruvic acid, and containing 200 µCi/ml ³⁵S-sulfate or ³H-leucine, or 10 µCi/ml of the

¹⁴C-amino acid mixture. The medium was collected, supplemented with 5 mM EDTA, 0.5 mM phenylmethylsulfonylfluoride, 0.04 mg/ml aprotinin and 1 μ g/ml pepstatin to inhibit protease activity, freed of 5 cellular debris by centrifugation for 20 minutes at 2,000 x G and stored at -20°C. Cell extracts were prepared by rinsing the cell layers with TBS and then scraping with a rubber policeman into 1 ml/well of ice cold cell lysis buffer: 0.05 M Tris-HCl, 0.5 M NaCl, 0.1% BSA, 1% NP-40, 10 0.5% Triton X-100, 0.1% SDS, pH 8.3. The cell extracts were clarified by centrifugation for 1.5 hours at 13,000 x G at 4°C.

Rabbit antiserum was prepared against a synthetic 15 peptide based on the first 15 residues of the mature form of the human decorin core protein (Asp-Glu-Ala-Ser-Gly-Ile-Gly-Pro-Glu-Val-Pro-Asp-Asp-Arg-Asp). The synthetic peptide and the antiserum against it have been described elsewhere (Krusius and Ruoslahti, 1986 supra.) Briefly, 20 the peptide was synthesized with a solid phase peptide synthesizer (Applied Biosystems, Foster City, CA) by using the chemistry suggested by the manufacturer. The peptide was coupled to keyhole limpet hemocyanin by using N-succinimidyl 3-(2-pyridyldithio) propionate (Pharmacia Fine 25 Chemicals, Piscataway, NJ) according to the manufacturer's instructions. The resulting conjugates were emulsified in Freund's complete adjuvant and injected into rabbits. Further injections of conjugate in Freund's incomplete adjuvant were given after one, two and three months. The 30 dose of each injection was equivalent to 0.6 mg of peptide. Blood was collected 10 days after the third and fourth injection. The antisera were tested against the glutaraldehyde-cross linked peptides and isolated decorin in ELISA (Engvall, Meth. Enzymol. 70:419-439 (1980)), in 35 immunoprecipitation and immunoblotting, and by staining cells in immunofluorescence, as is well known in the art.

Immunoprecipitations were performed by adding 20 μ l of antiserum to the conditioned medium or cell extract collected from duplicate wells and then mixing overnight at 4°C. Immunocomplexes were isolated by incubations for 2 hours at 4°C with 20 μ l of packed Protein A-agarose (Sigma). The beads were washed with the cell lysis buffer, with three tube changes, and then washed twice with phosphate-buffered saline prior to boiling in gel electrophoresis sample buffer containing 10% mercaptoethanol. Immunoprecipitated proteins were separated by SDS-PAGE in 7.5-20% gradient gels or 7.5% non-gradient gels as is well known in the art. Fluorography was performed by using Enlightning (New England Nuclear) with intensification screens. Typical exposure times were for 7-10 days at -70°C. Autoradiographs were scanned with an LKB Ultroscan XL Enhanced Laser Densitometer to compare the relative intensities and mobilities of the proteoglycan bands.

SDS-PAGE analysis of cell extracts and culture medium from COS-1 cells transfected with the decorin-pSV2 construct and metabolically radiolabeled with 35 S-sulfate revealed a sulfated band that was not present in mock-transfected cells. Immunoprecipitation with the antiserum raised against a synthetic peptide derived from the decorin core protein showed that the new band was decorin.

Expression of the construct mutated such that the serine residue which is normally substituted with a glycosaminoglycan (serine-4) was replaced by a threonine residue by SDS-PAGE revealed only about 10% of the level of proteoglycan obtained with the wild-type construct. The rest of the immunoreactive material migrated at the position of free core protein.

The alanine-mutated cDNA construct when expressed and analyzed in a similar manner yielded only core protein and

no proteoglycan form of decorin. Figure 1 shows the expression of decorin (lanes 1) and its threonine-4 (lanes 3) and alanine-4 (lanes 2) mutated core proteins expressed in COS cell transfectants. $^{35}\text{SO}_4$ -labeled (A) and ^3H -leucine labeled (B) culture supernatants were immunoprecipitated with rabbit antipeptide antiserum prepared against the NH_2 -terminus of human decorin.

10 Purification of Decorin and Decorin Core Protein from Spent Culture Media

Cells transfected with pSV2-decorin vector and amplified as described above and in Yamaguchi and 15 Ruoslahti, *Nature* 36:244-246 (1988), which is incorporated herein by reference, were grown to 90% confluence in 8 175 cm^2 culture flasks in nucleoside minus α -MEM supplemented with 9% dialyzed fetal calf serum, 2 mM glutamine, 100 units/ml penicillin and 100 $\mu\text{g}/\text{ml}$ streptomycin. At 90% 20 confluence culture media was changed to 25 ml per flask of nucleoside-free α -MEM supplemented with 6% dialyzed fetal calf serum which had been passed through a DEAE Sepharose Fast Flow column (Pharmacia) equilibrated with 0.25 M NaCl in 0.05 M phosphate buffer, pH 7.4. Cells were cultured 25 for 3 days, spent media was collected and immediately made to 0.5 mM phenylmethylsulfonyl fluoride, 1 $\mu\text{g}/\text{ml}$ pepstatin, 0.04 mg/ml aprotinin and 5 mM EDTA.

Four hundred milliliters of the spent media were first 30 passed through gelatin-Sepharose to remove fibronectin and materials which would bind to Sepharose. The flow-through fraction was then mixed with DEAE-Sepharose pre-equilibrated in 50 mM Tris/HCl, pH 7.4, plus 0.2 M NaCl and batch absorbed overnight at 4° C with gentle mixing. The 35 slurry was poured into a 1.6 x 24 cm column, washed extensively with 50 mM Tris/HCl, pH 7.4, containing 0.2 M NaCl and eluted with 0.2 M - 0.8 M linear gradient of NaCl

in 50 mM Tris/HCl, pH 7.4. Decorin concentration was determined by competitive ELISA as described in Yamaguchi and Ruoslahti, supra. The fractions containing decorin were pooled and further fractionated on a Sephadex gel 5 filtration column equilibrated with 8 M urea in the Tris-HCl buffer. Fractions containing decorin were collected.

The core protein is purified from cloned cell lines transfected with the pSV2-decorin/CP vector or the vector 10 containing the alanine-mutated cDNA and amplified as described above. These cells are grown to confluence as described above. At confluence the cell monolayer is washed four times with serum-free medium and incubated in a MEM supplemented with 2 mM glutamine for 2 hours. This 15 spent medium is discarded. Cells are then incubated with a MEM supplemented with 2 mM glutamine for 24 hours and the spent media are collected and immediately made to 0.5 mM phenylmethylsulfonyl fluoride, 1 μ g/ml pepstatin, 0.04 mg/ml aprotinin and 5 mM EDTA as serum-free spent media. 20 The spent media are first passed through gelatin-Sepharose and the flow-through fraction is then batch-absorbed to CM-Sepharose Fast Flow (Pharmacia Fine Chemicals, Piscataway, NJ) preequilibrated in 50 mM Tris/HCl, pH 7.4 containing 0.1 M NaCl. After overnight incubation at 4°C, the slurry 25 is poured into a column, washed extensively with the preequilibration buffer and eluted with 0.1M - 1M linear gradient of NaCl in 50 mM Tris/HCl, pH 7.4. The fractions containing decorin are pooled, dialyzed against 50 mM NH₄HCO₃ and lyophilized. The lyophilized material is 30 dissolved in 50 mM Tris, pH 7.4, containing 8M urea and applied to a Sephadex S-200 column (1.5 X 110 cm). Fractions containing decorin core proteins as revealed by SDS-polyacrylamide electrophoresis are collected and represent purified decorin core protein.

EXAMPLE II
BINDING OF TGFB TO DECORIN

a. Affinity Chromatography of TGFB on Decorin-Sepharose

5 Decorin and gelatin were coupled to cyanogen bromide-activated Sepharose (Sigma) by using 1 mg of protein per ml of Sepharose matrix according to the manufacturer's instructions. Commercially obtained TGFB-1 (Calbiochem, La Jolla, CA) was ^{125}I -labelled by the chloramine T method
10 (Frolik et al., J. Biol. Chem. 259:10995-11000 (1984)) which is incorporated herein by reference and the labeled TGFB was separated from the unreacted iodine by gel filtration on Sephadex G-25, equilibrated with phosphate buffered saline (PBS) containing 0.1% bovine serum albumin
15 (BSA) (Figure 2). $[^{125}\text{I}]$ -TGFB1 (5×10^5 cpm) was incubated in BSA-coated polypropylene tubes with 0.2 ml of packed decorin-Sepharose (●) or gelatin-Sepharose (○) in 2 ml of PBS pH 7.4, containing 1 M NaCl and 0.05% Tween 20. After overnight incubation, the affinity matrices were
20 transferred into BSA-coated disposable columns (Bio Rad) and washed with the binding buffer. Elution was effected first with 3 M NaCl in the binding buffer and then with 8 M urea in the same buffer. Fractions were collected, counted for radioactivity in a gamma counter and analyzed
25 by SDS-PAGE under nonreducing condition using 12% gels.

Figure 2A shows the radioactivity profile from the two columns and the SDS-PAGE analysis of the fractions is shown in Figure 2B. The TGFB-1 starting material contains a
30 major band at 25 kd. This band represents the native TGFB-1 dimer. In addition, there are numerous minor bands in the preparation. About 20-30% of the radioactivity binds to the decorin column and elutes with 8 M urea, whereas only about 2% of the radioactivity is present in the urea-
35 eluted fraction in the control fractionation performed on gelatin-Sepharose (Figure 2A). The decorin-Sepharose

nonbound fraction contains all of the minor components and some of the 25 kd TGF β -1, whereas the bound, urea-eluted fraction contains only TGF β -1 (Figure 2B). These results show that TGF β -1 binds specifically to decorin, since among 5 the various components present in the original TGF β -1 preparation, only TGF β -1 bound to the decorin-Sepharose affinity matrix and since there was very little binding to the control gelatin-Sepharose affinity matrix. The TGF β -1 that did not bind to the decorin-Sepharose column may have 10 been denatured by the iodination. Evidence for this possibility was provided by affinity chromatography of unlabeled TGF β -1 as described below.

In a second experiment, unlabeled TGF β -1 180 ng was 15 fractionated on decorin-Sepharose as described above for 125 I-TGF β .

TGF β -1 (180 ng) was incubated with decorin-Sepharose or BSA-agarose (0.2 ml packed volume) in PBS (pH 7.4) containing 1% BSA. After overnight incubation at 4°C, the 20 resins were washed with 15 ml of the buffer and eluted first with 5 ml of 3 M NaCl in PBS then with 5 ml of PBS containing 8 M urea. Aliquots of each pool were dialyzed against culture medium without serum and assayed for the inhibition of [3 H]thymidine incorporation in Mv1Lu cells 25 (Example III). The amounts of TGF β -1 in each pool were calculated from the standard curve of [3 H]thymidine incorporation obtained from a parallel experiment with known concentration of TGF β -1. The results show that the TGF β -1 bound essentially quantitatively to the decorin 30 column, whereas there was little binding to the control column (Table 1). The partial recovery of the TGF β -1 activity may be due to loss of TGF β -1 in the dialyses.

TABLE I

Decorin-Sepharose affinity chromatography of nonlabeled TGF β -1 monitored by growth inhibition assay in Mv1Lu cells.

5

	Elution	TGF β -1 (ng)	
		Decorin-Sepharose	BSA-Sepharose
	Flow through & wash	2.7 (2.3%)	82.0 (93.9%)
10	3 M NaCl	2.2 (1.8%)	1.3 (1.5%)
	8 M Urea	116.0 (95.9%)	4.0 (4.6%)

15 b. Binding of TGF β -1 to Decorin in a Microtiter Assay: Inhibition by Core Protein and Byglycan

The binding of TGF β -1 to decorin was also examined in a microtiter binding assay. To perform the assay, the wells of a 96-well microtiter plate were coated overnight 20 with 2 μ g/ml of recombinant decorin in 0.1 M sodium carbonate buffer, pH 9.5. The wells were washed with PBS containing 0.05% Tween (PBS/Tween) and samples containing 5 \times 10⁴ cpm of [¹²⁵I]-TGF β -1 and various concentrations of competitors in PBS/Tween were added to each well. The 25 plates were then incubated at 37°C for 4 hours (at 4°C overnight in experiments with chondroitinase ABC-digested proteoglycans), washed with PBS/Tween and the bound radioactivity was solubilized with 1% SDS in 0.2 M NaOH. Total binding without competitors was about 4% under the 30 conditions used. Nonspecific binding, determined by adding 100-fold molar excess of unlabeled TGF β -1 over the labeled TGF β -1 to the incubation mixture, was about 13% of total binding. This assay was also used to study the ability of other decorin preparations and related proteins to compete 35 with the interaction.

Completion of the decorin binding was examined with the following proteins (Figure 3; symbols are indicated in the section of BRIEF DESCRIPTION OF THE FIGURES):

5 Decorin isolated from bovine skin and biglycan isolated from bovine articular cartilage (PGI and PGII, obtained from Dr. Lawrence Rosenberg, Montefiore Medical Center, N.Y.; and described in Rosenberg et al., J. Biol. Chem. 250:6304-6313, (1985), incorporated by reference
10 herein), chicken cartilage proteoglycan (provided by Dr. Paul Goetinck, La Jolla Cancer Research Foundation, La Jolla, CA, and described in Goetinck, P.F., in THE GLYCOCONJUGATES, Vol. III, Horwitz, M.I., Editor, pp. 197-217, Academic Press, NY). For the preparation of core
15 proteins, proteoglycans were digested with chondroitinase ABC (Seikagaku, Tokyo, Japan) by incubating 500 µg of proteoglycan with 0.8 units of chondroitinase ABC in 250 µl of 0.1 M Tris/Cl, pH 8.0, 30 mM sodium acetate, 2 mM PMSF, 10 mM N-ethylmaleimide, 10 mM EDTA, and 0.36 mM pepstatin
20 for 1 hour at 37°C. Recombinant decorin and decorin isolated from bovine skin (PGII) inhibited the binding of [¹²⁵I]-TGF β -1, as expected (Figure 3A). Biglycan isolated from bovine articular cartilage was as effective an inhibitor as decorin. Since chicken cartilage
25 proteoglycan, which carries many chondroitin sulfate chains, did not show any inhibition, the effect of decorin and biglycan is unlikely to be due to glycosaminoglycans. Bovine serum albumin did not show any inhibition. This notion was further supported by competition experiments
30 with the mutated decorin core protein (not shown) and chondroitinase ABC-digested decorin and biglycan (Figure 3B). Each of these proteins was inhibitory, whereas cartilage proteoglycan core protein was not. The decorin and biglycan core proteins were somewhat more active than
35 the intact proteoglycans. Bovine serum albumin treated with chondroitinase ABC did not show any inhibition. Additional binding experiments showed that [¹²⁵I]-TGF β -1

bound to microtiter wells coated with biglycan or its chondroitinase-treated core protein. These results show that TGF β -1 binds to the core protein of decorin and biglycan and implicates the leucine-rich repeats these 5 proteins share as the potential binding sites.

EXAMPLE III

ANALYSIS OF THE EFFECT OF DECORIN ON CELL PROLIFERATION
STIMULATED OR INHIBITED BY TGF β -1

10 The ability of decorin to modulate the activity of TGF β -1 was examined in [3 H]thymidine incorporation assays. In one assay, an unamplified CHO cell line transfected only with pSV2dhfr (control cell line A in reference 1, called CHO cells here) was used. The cells were maintained in 15 nucleoside-free alpha-modified minimal essential medium (α -MEM, GIBCO, Long Island, NY) supplemented with 9% dialyzed fetal calf serum (dFCS) and [3 H]thymidine incorporation was assayed as described (Cheifetz et al., Cell 48:409-415 (1987)). TGF β -1 was added to the CHO cell cultures at 5 20 ng/ml. At this concentration, it induced a 50% increase of [3 H]thymidine incorporation in these cells. Decorin or BSA was added to the medium at different concentrations. The results are shown in Figure 4A. The data represent percent neutralization of the TGF β -1-induced growth stimulation, 25 i.e., [3 H]thymidine incorporation, in the absence of either TGF β -1 or decorin = 0%, incorporation in the presence of TGF β -1 but not decorin = 100%. Each point shows the mean \pm standard deviation of triplicate samples. Decorin (●) BSA (○).

30 Decorin neutralized the growth stimulatory activity of TGF β -1 with a half maximal activity at about 5 μ g/ml. Moreover, additional decorin suppressed the [3 H]-thymidine incorporation below the level observed without any added TGF β -1, demonstrating that decorin also inhibited TGF β made 35 by the CHO cells themselves. Both the decorin-expressor

and control CHO cells produced an apparently active TGF β concentration of about 0.25 ng/ml concentration into their conditioned media as determined by the inhibition of growth of the mink lung epithelial cells. (The assay could be 5 performed without interference from the decorin in the culture media because, as shown below, the effect of TGF β on the mink cells was not substantially inhibited at the decorin concentrations present in the decorin-producer media.)

10 Experiments in MvLu mink lung epithelial cells (American Type Culture Collection CCL64) also revealed an effect by decorin on the activity of TGF β -1. Figure 4B shows that in these cells, the growth of which is measured by thymidine incorporation, had been suppressed by TGF β -1. 15 Assay was performed as in Figure 4A, except that TGF β -1 was added at 0.5 ng/ml. This concentration of TGF β induces 50% reduction of [3 H]-thymidine incorporation in the MvLu cells. The data represent neutralization of TGF β -induced growth inhibition; i.e., [3 H]-thymidine incorporation in 20 the presence of neither TGF β or decorin = 100%; incorporation in the presence of TGF β but not decorin = 0%.

EXAMPLE IV

NEW DECORIN-BINDING FACTOR THAT CONTROLS CELL SPREADING
25 AND SATURATION DENSITY

Analysis of the decorin contained in the overexpressor culture media not only uncovered the activities of decorin described above, but also revealed the presence of other 30 decorin-associated growth regulatory activities. The overexpressor media were found to contain a TGF β -like growth inhibitory activity. This was shown by gel filtration of the DEAE-isolated decorin under dissociating conditions. Serum-free conditioned medium of decorin 35 overexpressor CHO-DG44 cells transfected with decorin cDNA was fractionated by DEAE-Sephadex chromatography in a

neutral Tris-HCl buffer and fractions containing growth inhibitory activity dialyzed against 50 mM NH₄HCO₃, lyophilized and dissolved in 4 M with guanidine-HCl in a sodium acetate buffer, pH 5.9. The dissolved material was 5 fractionated on a 1.5 x 70 cm Sepharose CL-6B column equilibrated with the same guanidine-HCl solution. The fractions were analyzed by SDS-PAGE, decorin ELISA and cell growth assays, all described above. Three protein peaks were obtained. One contained high molecular weight 10 proteins such as fibronectin (m.w. 500,000) and no detectable growth regulatory activities, the second was decorin with the activities described under Example III and the third was a low molecular weight (10,000-30,000-dalton) fraction that had a growth inhibitory activity in the mink 15 cell assay and stimulated the growth of the CHO cells. Figure 5 summarizes these results. Shown are the ability of the gel filtration fractions to affect [³H]-thymidine incorporation by the CHO cells and the concentration of decorin as determined by enzyme immunoassay. Shown also 20 (arrows) are the elution positions of molecular size markers: BSA, bovine serum albumin (Mr=66,000); CA, carbonic anhydrase (Mr=29,000); Cy, cytochrome c (Mr=12,400); AP, aprotinin (Mr=6,500); TGF, [¹²⁵I]TGF β -1 (Mr=25,000).

25 The nature of the growth regulatory activity detected in the low molecular weight fraction was examined with an anti-TGF β -1 antiserum. The antiserum was prepared against a synthetic peptide from residues 78-109 of the human mature TGF β -1. Antisera raised by others against a cyclic 30 form of the same peptide, the terminal cysteine residues of which were disulfide-linked, have previously been shown to inhibit the binding of TGF β -1 to its receptors (Flanders et al., Biochemistry 27:739-746 (1988), incorporated by reference herein). The peptide was synthesized in an 35 Applied Biosystems solid phase peptide synthesizer and purified by HPLC. A rabbit was immunized subcutaneously

with 2 mg per injection of the peptide which was mixed with 0.5 mg of methylated BSA (Sigma, St. Louis, MO) and emulsified in Freund's complete adjuvant. The injections were generally given four weeks apart and the rabbit was 5 bled approximately one week after the second and every successive injection. The antisera used in this work has a titer (50% binding) of 1:6,000 in radioimmunoassay, bound to TGF β -1 in immunoblots.

10 This antiserum was capable of inhibiting the activity of purified TGF β -1 on the CHO cells. Moreover, as shown in Figure 5, the antiserum also inhibited the growth stimulatory activity of the low molecular weight fraction as determined by the [3 H]-thymidine incorporation assay on 15 the CHO cells. Increasing concentrations of an IgG fraction prepared from the anti-TGF β -1 antiserum suppressed the stimulatory effect of the low molecular weight fraction in a concentration-dependent manner (●). IgG from a normal rabbit serum had no effect in the assay (○).

20 The above result identified the stimulatory factor in the low molecular weight fraction as TGF β -1. However, TGF β -1 is not the only active compound in that fraction. Despite the restoration of thymidine incorporation by the anti-TGF β -1 antibody shown in Figure 5, the cells treated 25 with the low molecular weight fraction were morphologically different from the cells treated with the control IgG or cells treated with antibody alone. This effect was particularly clear when the antibody-treated, low molecular weight fraction was added to cultures of H-ras transformed 30 NIH 3T3 cells (Der et al., Proc. Natl. Acad. Sci. USA 79:3637-3640 (1982)). As shown in Figure 6, cells treated with the low molecular weight fraction and antibody (micrograph in panel B) appeared more spread and contact inhibited than the control cells (micrograph in panel A). 35 This result shows that the CHO cell-derived recombinant decorin is associated with a cell regulatory factor, MRF,

distinct from the well characterized TGFB's.

Additional evidence that the new factor is distinct from TGFB-1 came from HPLC experiments. Further separations of the low molecular weight from the Sepharose 5 CL-6B column was done on a Vydac C4 reverse phase column (1 x 25 cm, 5 μ m particle size, the Separations Group, Hesperia, CA) in 0.1% trifluoroacetic acid. Bound proteins were eluted with a gradient of acetonitrile (22-40%) and 10 the fractions were assayed for growth-inhibitory activity in the mink lung epithelial cells and MRF activity in H-ras 3T3 cells. The result showed that the TGFB-1 activity eluted at the beginning of the gradient, whereas the MRF activity eluted toward the end of the gradient.

15 The deposit of the CHO-DG44 cells transfected with pSV2-decorin was made under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purpose of Patent Procedure and the 20 Regulations thereunder (Budapest Treaty). This assures maintenance of a viable culture for 30 years from date of deposit. The deposits will be made available by ATCC under the terms of the Budapest Treaty, and subject to an 25 agreement between Applicants and ATCC which assures permanent and unrestricted availability upon issuance of the pertinent U.S. patent. The Assignee herein agrees that if the culture on deposit should die or be lost or destroyed when cultivated under suitable conditions, it will be promptly replaced upon notification with a viable specimen of the same culture. Availability of the deposits 30 is not to be construed as a license to practice the invention in contravention of the rights granted under the authority of any government in accordance with its patent laws.

35 The deposit was made for the convenience of the relevant public and does not constitute an admission that

a written description would not be sufficient to permit practice of the invention to the specific construct. Set forth hereinabove is a complete written description enabling a practitioner of ordinary skill to duplicate the 5 construct deposited and to construct alternative forms of DNA, or organisms containing it, which permit practice of the invention as claimed.

Although the invention has been described with 10 reference to the presently-preferred embodiments, it should be understood that various modifications can be made without departing from the spirit of the invention. Accordingly, the invention is limited only by the following claims.

What is claimed is:

1. A method of inhibiting an activity of a cell regulatory factor comprising contacting the cell regulatory factor with a purified polypeptide, wherein the polypeptide comprises a cell regulatory factor binding domain of a protein and wherein the protein is characterized by a leucine-rich repeat of about 24 amino acids.
5
2. The method of claim 1, wherein the cell regulatory factor is a TGF β .
3. The method of claim 2, wherein the TGF β is TGF β -1.
4. The method of claim 2, wherein the TGF β is TGF β -2.
5. The method of claim 1, wherein the cell regulatory factor is a protein, designated MRF, having a molecular weight of about 20 kd, which can be isolated from CHO cells, which copurifies decorin under nondissociating conditions, separates from decorin under dissociating conditions, changes the morphology of transformed 3T3 cells, and has an activity which is not inhibited with anti-TGF β -1 antibody.
5
6. The method of claim 1, wherein the inhibited activity is promotion of cell proliferation.
7. The method of claim 1, wherein the inhibited activity is suppression of proliferation.
8. The method of claim 1, wherein the inhibited activity is promotion of extracellular matrix production.
9. The method of claim 1, wherein the protein is decorin.

10. The method of claim 1, wherein the protein is biglycan.
11. The method of claim 1, wherein the protein is fibromodulin.
12. A purified compound comprising a cell regulatory factor attached to a purified polypeptide, wherein the polypeptide comprises a cell regulatory factor binding domain of a protein and wherein the protein is characterized by a leucine-rich repeat of about 24 amino acids.
5
13. The compound of claim 12, wherein the cell regulatory factor is a TGF β .
14. The compound of claim 13, wherein the TGF β is TGF β -1.
15. The compound of claim 13, wherein the TGF β is TGF β -2.
16. The compound of claim 12, wherein the cell regulatory factor is a protein having a molecular weight of about 20 kd, which can be isolated from CHO cells, which copurifies decorin under nondissociating conditions, separates from decorin under dissociating conditions, changes the morphology of transformed 3T3 cells, and has an activity which is not inhibited with anti-TGF β -1 antibody.
5
17. The compound of claim 12, wherein the protein is decorin.
18. The compound of claim 12, wherein the protein is biglycan.
19. The compound of claim 12, wherein the protein is fibromodulin.

20. A purified protein, designated MRF, having a molecular weight of about 20 kd, which can be isolated from CHO cells, copurifies with decorin under nondissociating conditions, separates from decorin under dissociating 5 conditions, changes the morphology of transformed 3T3 cells, and has an activity which is not inhibited with anti-TGF β -1 antibody.

21. A method of purifying a cell regulatory factor comprising contacting the cell regulatory factor with a protein which binds the cell regulatory factor and has a leucine-rich repeat of about 24 amino acids and detecting 5 the regulatory factor which becomes bound to the protein.

22. The method of claim 21, wherein the protein is decorin.

23. The method of claim 21, wherein the regulatory factor is a TGF β .

24. The method of claim 21, wherein the regulatory factor is a protein, designated MRF, having a molecular weight of about 20 kd which can be isolated from CHO cells, copurifies under nondissociating conditions, separates from 5 decorin under dissociating conditions, changes the morphology of transformed 3T3 cells, and has an activity which is not inhibited with anti-TGF β -1 antibody.

25. A method of identifying or detecting a cell regulatory factor in a sample comprising contacting the sample containing the cell regulatory factor with a purified polypeptide, wherein the polypeptide comprises a cell 5 regulatory factor binding domain of a protein and wherein the protein is characterized by a leucine-rich repeat of about 24 amino acids.

26. The method of claim 25, wherein the cell regulatory factor is TGFB-1.
27. A method of treating a pathology caused by a TGFB regulated activity comprising contacting the TGFB with a purified polypeptide, wherein the polypeptide comprises a TGFB binding domain of a protein and wherein the protein is characterized by a leucine-rich repeat of about 24 amino acids, whereby the pathology causing activity is prevented or reduced.
5
28. The method of claim 27, wherein the protein is decorin.
29. The method of claim 27, wherein the protein is biglycan.
30. The method of claim 27, wherein the pathology is selected from the group consisting of a cancer, a fibrotic disease, and glomerulonephritis.
31. A method of identifying or detecting a protein which is characterized by a leucine-rich repeat of about 24 amino acids comprising contacting a cell regulatory factor with the protein and detecting those proteins which become bound to the cell regulatory factor.
5
32. A method of preventing the inhibition of a cell regulatory factor activity comprising contacting a protein characterized by a leucine-rich repeat of about 24 amino acids which inhibits the cell regulatory factor activity with a molecule which inhibits the activity of the protein.
5
33. Method of claim 32, wherein the molecule is an antibody.

34. The method of claim 32, wherein the cell regulatory factor is TGF β and the prevention of inhibition of TGF β activity results in a promotion of wound healing.

1 / 6

FIG. 1A



200-

97-

68-

43-

29-

200-

97-

68-

43-

29-

1 2 3 4

1 2 3 4

FIG. 2B

1 2 3 4 5 6 7 8 9 10 11 12 13 14



94-

67-

43-

30-

20-

14-

**SUBSTITUTE SHEET**

2 / 6

FIG. 2A





FIG. 5B



SUBSTITUTE SHEET

3 / 6







FIG. 3A



SUBSTITUTE SHEET

4 / 6

**FIG. 4A****SUBSTITUTE SHEET**




FIG. 5A

SUBSTITUTE SHEET

6 / 6




FIG. 6A



FIG. 6B

SUBSTITUTE SHEET

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US91/00453

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶

According to International Patent Classification (IPC) or to both National Classification and IPC
 IPC(5): C12N 5/00; C07K 13/00
 U.S. CL.: 435/240.1, 240.2; 530/395, 399, 412, 413

II. FIELDS SEARCHED

Classification System	Minimum Documentation Searched ⁷
	Classification Symbols
U.S.	.435/240.1, 240.2; 530/395, 399, 412, 413, 842

Documentation Searched other than Minimum Documentation
 to the Extent that such Documents are Included in the Fields Searched ⁸

Databases: Chemical Abstracts Service online (File CA, 1967-1991; File Biosis 1969-1991) Search Terms: Decorin, PG-I, PG-II, TGF Beta, Protein binding, Growth factor, Proteoglycan, PG-ST, PG-STII

III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹

Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
X. P	Nature. Volume 346. Issued 19 July 1990 Yamaguchi et al. "Negative regulation of transforming growth factor- by the proteoglycan decorin". pages 281-284. See entire article.	1-3.6-9. 12-14.17.21 -23
Y	The Journal of Biological Chemistry. Volume 263. No. 17. Issued 15 June 1988. Segarini et al. "The high molecular Weight receptor to Transforming Growth Factor- contains glycosaminoglycan chains". pages 8366-8370. See entire article.	1-3.6-9. 12-14.17. 21-23
Y	Annual Review Cell Biology. Volume 4. Issued 1988. Ruoslahti. "Structure and biology of proteoglycans", pages 229-255.	1-3.6-9. 12-14.17 21-23
Y	Nature. Volume 336. Issued 17 November 1988. Yamaguchi et al. "Expression of human proteoglycan in chinese hamster ovary cells inhibits cell proliferation". pages 244-246.	1-3.6.9,12- 14.17.21-23

* Special categories of cited documents: ¹⁰

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search


16 April 1991

Date of Mailing of this International Search Report

14 JUN 1991

International Searching Authority

ISA/US

Signature of Authorized Officer

 Gail E. Poulos

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V. OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. Claim numbers because they relate to subject matter not required to be searched by this Authority, namely:

2. Claim numbers because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claim numbers because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

This International Searching Authority found multiple inventions in this international application as follows:

SEE ATTACHMENT

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.

2. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:

3. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers: 1-3, 6-9, 12-14, 17, 21-23 drawn to decorin and TGF-B1

Telephone practice

4. As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

The additional search fees were accompanied by applicant's protest.

No protest accompanied the payment of additional search fees.

ATTACHMENT TO FORM PCT/ISA/210, PART VI

VI. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING:

J. Claims 1-3, 6-9, 12-14, 17, 21-23 drawn to a method of inhibiting an activity of TGFB1 with decorin a composition and a method of purifying TGF-B1; class 435, subclass 240; class 530, subclass 395; and class 530, subclass 412.

II. Claims 1-3, 6-8 and 10; drawn to a method of inhibiting TGF-B1 with biglycan, class 435, subclass 240.1.

III. Claims 1, 2, 4, 6-9: drawn to a method of inhibiting TGF B2 with decorin; class 435, subclass 240.1.

IV. Claims 1, 2, 4, 6-8, 10; drawn to a method of inhibiting TGF B2 with biglycan; class 435, subclass 240.1.

V. Claims 1-3, 6-8, 11; drawn to a method of inhibiting TGF B1 with fibromodulin; class 435, subclass 240.1.

VI. Claims 1, 2, 4, 6-8, 11 drawn to a method of inhibiting TGF B2 with fibromodulin; class 435, subclass 240.1.

VII. Claims 1, 5, 9 drawn to a method of inhibiting MRF with decorin; class 435, subclass 240.1.

VIII. Claims 1, 5, 10 drawn to a method of inhibiting MRF with biglycan; class 435, subclass 240.1.

IX. Claims 1, 5, 11 drawn to a method of inhibiting MRF

with fibromodulin; class 435, subclass 240.1.

X. Claims 12-14, 17 drawn to a compound comprising TGF B1, and biglycan; class 530, subclass 395.

XI. Claims 12-14, 19 drawn to a compound comprising TGF B1 and fibromodulin; class 530, subclass 395.

XII. Claims 12, 13, 15, 17 drawn to a compound comprising TGF B2 and Decorin; class 530, subclass 395.

XIII. Claims 12, 13, 15, 18 drawn to a compound comprising TGF B2 and biglycan; class 530, subclass 395.

XIV. Claims 12, 13, 15, 19 drawn to a compound comprising TGF B2 and fibromodulin; class 530, subclass 395.

XV. Claims 12, 16, 17 drawn to a compound comprising MRF and Decorin; class 530, subclass 395.

XVI. Claims 12, 16, 18 drawn to a compound comprising MRF and biglycan; class 530, subclass 395.

XVII. Claims 12, 16, 19 drawn to a compound comprising MRF and fibromodulin; class 530, subclass 395.

XVIII. Claim 20 drawn to MRF per se, class 530, subclass 399.

XIX. Claims 21, 22, 24 drawn to a method of purifying MRF with Decorin; class 530, subclass 412.

XX. Claims 25 and 26 drawn to a method of identifying or detecting a cell regulatory factor; class 435, subclass 7.1

XXI. Claims 27, 28, 30 drawn to a method of treating a TGFB pathology with Decorin; class 514, subclass 8.

XXII. Claims 27, 29, 20 drawn to a method of treating a TGF B pathology with biglycan; class 514, subclass 8.

XXIII. Claim 31 drawn to a method of identifying or detecting a leucinerich polypeptide; class 435, subclass 7.1.

XXIV. Claims 32-34 drawn to a method of preventing inhibition of a cell regulatory factor; class 424, subclass 85.8.

Reasons for holding lack of Unity of Invention:

The inventions as defined by groups II-XXIV are functionally distinct from the invention of group I drawn to a composition comprising decorin and TGF B1, a method of purifying TGF_B1 and a method of using decorin. The other groups are drawn to additional different compounds, and methods of using and methods of purifying.